计算机/软件开发 指南针（300803.SZ） 2026 年 02 月 01 日 投资评级：买入（维持） | 日期 | 2026/1/30 | | --- | --- | | 当前股价(元) | 124.00 | | 一年最高最低(元) | 179.01/50.40 | | 总市值(亿元) | 756.14 | | 流通市值(亿元) | 750.62 | | 总股本(亿股) | 6.10 | | 流通股本(亿股) | 6.05 | | 近 3 个月换手率(%) | 272.32 | 股价走势图 数据来源：聚源 -50% 0% 50% 100% 150% 200% 2025-02 2025-06 2025-10 指南针 沪深300 相关研究报告 《销售费用环比增长，关注 Q4 高端品 销售情况—指南针 2025 三季报点评》 -2025.10.26 《新增客户数同比高增，下半年订单 弹性可期—指南针 2025 中报点评》 -2025.8.28 《扣非净利润符合预期，业绩和估值 高弹性特征突出—指南针 2025一季报 点评》-2025.4.27 业绩符合预期，证券业务高增体现协同效应 ——指南针 2025 年报点 ...

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Insights - The company is expected to achieve a net profit attributable to shareholders of between 0.62 billion to 0.86 billion yuan in 2025, representing a year-on-year growth of 50.82% to 109.21%, with a median estimate of 0.74 billion yuan [3] - The company anticipates a significant increase in net profit for Q4 2025, projected between 0.14 billion to 0.38 billion yuan, reflecting a year-on-year growth of 278.34% to 920.05% [3] - The report highlights a strong demand in multiple markets, particularly in overseas commercial and residential energy storage, which is expected to drive revenue growth [4][5] Financial Summary - The company forecasts a revenue of 3.657 billion yuan for 2025, with a year-on-year increase of 82.4% [6] - The projected net profit for 2026 is 498 million yuan, showing a substantial increase of 523.5% compared to 2025 [6] - The earnings per share (EPS) for 2025 is estimated at 0.33 yuan, with a projected EPS of 2.03 yuan for 2026 [6] Business Growth - The company has seen rapid growth in its overseas commercial and residential energy storage sectors, with significant advancements in domestic commercial storage and light-duty power businesses [4] - The residential storage business is optimizing product performance and cost structure, leveraging its brand reputation in the European market to enhance global market share [4] - The light-duty power segment is focusing on expanding its customer base in the two- and three-wheeler battery swap ecosystem, creating new growth drivers [4]

Investment Rating - The report gives a positive investment rating for Aide Technology, highlighting its leadership in orthopedic consumables and the dual opportunities presented by aging population and domestic substitution [1]. Core Viewpoints - Aide Technology focuses on the research, production, and sales of orthopedic medical devices, covering spinal, trauma, joint, and sports medicine fields, with a projected 13.76% increase in net profit attributable to shareholders in 2025 [1][10]. - The company ranks third in the domestic market for spinal vertebroplasty systems and sixth for spinal implant medical devices, indicating a strong market position [1][11]. - The orthopedic medical device market in China is expected to grow from 193 billion yuan in 2016 to 246 billion yuan in 2024, with a compound annual growth rate (CAGR) of 3.08% [2][9]. Company Overview - Aide Technology is a national high-tech enterprise with various accolades, including recognition as a "specialized and innovative small and medium-sized enterprise" in Jiangsu Province [1][11]. - The company has developed a comprehensive product line that includes vertebroplasty systems, trauma implants, and wound healing products, with a focus on clinical needs [10][15]. - As of November 24, 2025, Aide Technology holds 110 patents, including 45 invention patents, and has established a strong technical advantage in its niche markets [11][12]. Financial Performance - For the first three quarters of 2025, the company reported revenues of 222.69 million yuan and a net profit of 59.55 million yuan, with forecasts for 2025 showing revenues of 307.48 million yuan and net profits of 76.37 million yuan [1][2]. - The company’s gross profit margins have shown slight fluctuations, with rates of 62.45%, 57.80%, 58.05%, and 58.89% from 2022 to the first half of 2025 [7][12]. Industry Insights - The report notes that the trend of centralized procurement in the orthopedic industry is stabilizing, reducing the likelihood of further significant price drops [2][9]. - The orthopedic implant market has seen a decline in 2022-2023 due to centralized procurement policies, but opportunities remain in non-procurement products and overseas markets [2][9]. - The aging population in China is expected to drive demand for orthopedic products, as the incidence of related diseases increases [2][9].

Investment Rating - The report does not explicitly state an investment rating for the company [1]. Core Insights - The company, Aide Technology, is a leading player in the orthopedic consumables sector, focusing on the full chain of orthopedic medical devices, including spinal, trauma, and sports medicine products, and is positioned to benefit from both aging population trends and domestic substitution opportunities [1][10]. - The company is expected to achieve a revenue of 307.48 million yuan and a net profit of 76.37 million yuan in 2025, representing year-on-year growth of 11.87% and 13.76% respectively [1]. - The orthopedic implant medical device market in China is projected to grow from 19.3 billion yuan in 2016 to 24.6 billion yuan in 2024, with a compound annual growth rate (CAGR) of 3.08% [2][9]. Company Overview - Aide Technology specializes in the research, production, and sales of orthopedic consumables, with a product range that includes spinal, trauma, sports medicine, and wound healing products [1][10]. - The company has been recognized as a national high-tech enterprise and has received various accolades, including being named a "Suzhou Brand Product" for its vertebroplasty system and external fixation bracket [1][11]. - As of November 24, 2025, the company holds 110 patents, including 45 invention patents, and has established a strong technical foundation in several core technologies [11]. Financial Performance - For the first three quarters of 2025, the company reported revenues of 222.69 million yuan and a net profit of 59.55 million yuan [1]. - The company’s gross profit margins for 2022 to the first half of 2025 were 62.45%, 57.80%, 58.05%, and 58.89% respectively [7][9]. - The company’s revenue structure is heavily reliant on manufacturing products, which accounted for 96.29% of total revenue in the first half of 2025 [41]. Industry Analysis - The orthopedic industry is experiencing a trend of price reductions due to centralized procurement policies, but the impact is expected to moderate, allowing for potential growth in non-procurement products and overseas markets [2]. - The market for vertebroplasty consumables in China grew from 800 million yuan in 2016 to 2.171 billion yuan in 2022, although it faced a decline in 2023 due to procurement policies [2][9]. - The aging population in China is expected to drive demand for orthopedic products, as the proportion of individuals aged 65 and older is steadily increasing [9].

Investment Rating - The industry investment rating is "Overweight" (maintained) [1] Core Insights - The report highlights the ongoing revival of the yellow wine industry, with a clear growth logic and significant price increases for premium products [3][4] - The trend of product premiumization is effectively taking shape, with leading companies optimizing their structures and upgrading their offerings [4] - The yellow wine sector is making strides towards national expansion, although it still faces challenges in breaking regional perceptions [6] - The report anticipates sustained growth in the yellow wine industry, driven by product, channel, and marketing upgrades [7] Summary by Sections Industry Overview - The yellow wine sector has shown a remarkable price increase, with stocks like Kuaijishan rising approximately 90% in 2025, significantly outperforming other alcoholic beverages [3] - The market is expected to benefit from the upcoming national standards for prepared dishes, which may enhance market concentration [3] Product Development - The high-end product strategy is yielding results, with successful transitions from "meal wine" to "social/banquet wine" [4] - Young consumers are becoming a core growth segment, with innovative products like "one day one smoke" sparkling yellow wine gaining popularity [5] Market Expansion - The current market share of yellow wine in regions outside Jiangsu, Zhejiang, and Shanghai is low, indicating potential for growth as companies push for national penetration [6] - Leading firms are adopting a multi-faceted approach to overcome regional barriers, focusing on product innovation and cultural empowerment [6] Future Trends - The report identifies three key trends that will continue to support the yellow wine industry's revival: stable growth among leading companies, conversion of short-term hits into long-term loyalty, and cultural value integration into consumer habits [7]

行业走势图 -10% 0% 10% 19% 29% 2025-02 2025-06 2025-10 食品饮料 沪深300 数据来源：聚源 相关研究报告 食品饮料 2026 年 01 月 30 日 投资评级：看好（维持） 2025 年以来，白酒的机构配置比例持续降低，业绩也在承压，股价面临估值和 业绩双杀。但从白酒板块历史上看，白酒一直跟随宏观环境呈现出较强周期性， 现在随着库存出清，行业从被动应对进入主动调整，预计 2026 年预期逐步筑底 企稳，后续随着居民资产负债表修复，消费意愿提升，从而进入下一个上行周期。 白酒股价下行，基金持仓再创新低 四季度以来白酒板块受指数基金卖出权重股影响表现不佳，基金重仓白酒比例由 2025Q3 的 3.2%回落至 2025Q4 的 2.9%水平，环比回落 0.3pct。如果观察全市场 基金口径，基金重仓白酒比例由 2025Q3 的 5.5%回落到 2025Q4 的 5.1%。这反 映出主动权益与被动基金均在减配白酒。主要原因是 2025 年以来，白酒产品价 格持续下行，市场对行业长期需求有所担忧。主动基金前十大重仓股中白酒仅有 贵州茅台，且从 Q3 末第 7 位下降至 Q4 ...

传媒/游戏Ⅱ 吉比特（603444.SH） 投资评级：买入（维持） | 日期 | 2026/1/29 | | --- | --- | | 当前股价(元) | 475.50 | | 一年最高最低(元) | 668.00/198.21 | | 总市值(亿元) | 342.56 | | 流通市值(亿元) | 342.56 | | 总股本(亿股) | 0.72 | | 流通股本(亿股) | 0.72 | | 近 3 个月换手率(%) | 157.33 | 股价走势图 数据来源：聚源 -80% 0% 80% 160% 240% 2025-02 2025-06 2025-10 吉比特 沪深300 相关研究报告 《《九牧之野》上线在即，看好新游持 续驱动公司成长—公司信息更新报 告》-2025.12.12 《出海及新游或持续驱动业绩高增长 —公司信息更新报告》-2025.10.29 《Q2 业绩高增，高分红延续，新游及 出海驱动成长 —公司信息更新报告》 -2025.8.20 方光照（分析师） fangguangzhao@kysec.cn 2026 年 01 月 30 日 证书编号：S0790520030004 2025 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][3] Core Views - The company is expected to see significant growth in 2025, with a forecasted net profit attributable to shareholders of 1.69-1.86 billion yuan, representing a year-on-year increase of 79-97%. The non-recurring net profit is projected to be 1.65-1.80 billion yuan, reflecting an 88-105% increase [3][4] - The anticipated growth is primarily driven by the new game launches in 2025, including "杖剑传说," "问剑长生," and "道友来挖宝," which are expected to contribute incremental profits [3][4] - The company has a strong long-term operational capability, as evidenced by the performance of existing games and the potential of new releases to enhance revenue [4][5] Financial Summary - The company's revenue is projected to increase from 4.185 billion yuan in 2023 to 6.102 billion yuan in 2025, with a year-on-year growth rate of 65.1% [6][8] - The net profit attributable to shareholders is expected to rise from 1.125 billion yuan in 2023 to 1.746 billion yuan in 2025, marking an 84.8% increase [6][8] - The gross margin is forecasted to improve from 88.5% in 2023 to 93.7% in 2025, indicating strong profitability [6][9] - The price-to-earnings (P/E) ratio is projected to decrease from 30.4 in 2023 to 19.6 in 2025, suggesting a more attractive valuation over time [6][8] Game Development and Market Position - The company is focusing on high-frequency content updates and building a trading ecosystem to create enduring games, with "问道手游" showing resilience in revenue generation [4][5] - Upcoming titles like "九牧之野" and "道友来挖宝" are expected to perform well based on initial rankings and user engagement metrics [4][5] - The company has several projects in development, including unique game mechanics that are expected to contribute to future revenue growth [5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company is expected to achieve significant growth in net profit, with a forecasted net profit of 83 million yuan for 2025, representing a year-on-year increase of 153.1%. The net profit for 2026 and 2027 is projected to be 158 million yuan and 297 million yuan, respectively [4][7] - The company has a strong positioning in the AI programming sector, with the launch of two AI programming products, SnapDevelop and EazyDevelop, which are expected to enhance development efficiency and attract a wide user base [5] Financial Summary - The company’s revenue is projected to grow from 418 million yuan in 2025 to 785 million yuan in 2027, with year-on-year growth rates of 29.4%, 35.8%, and 38.1% respectively [7] - The gross profit margin is expected to improve from 48.8% in 2025 to 58.0% in 2027, indicating enhanced profitability [10] - The earnings per share (EPS) is forecasted to increase from 0.69 yuan in 2025 to 2.45 yuan in 2027, reflecting strong earnings growth [7][10]

Group 1: Macro Economic Insights - The Federal Reserve maintained interest rates in the range of 3.5%-3.75% during the January FOMC meeting, indicating a stable economic expansion in the U.S. [5][6] - The labor market's downward trend and inflation risks have eased, suggesting that maintaining stable interest rates is the best choice for the short term [7][8] - Market reactions post-FOMC meeting showed little change in risk appetite, with the Dow Jones and Nasdaq indices experiencing slight increases [8] Group 2: Industrial Profit Insights - In December 2025, industrial profits for large-scale enterprises grew by 0.6% year-on-year, marking a return to positive growth after three consecutive years of decline [10][11] - The profit structure within the industrial sector is showing signs of divergence, with the equipment manufacturing sector becoming a significant driver of profit growth [13] - High-tech manufacturing profits increased by 13.3% year-on-year, significantly outpacing the average growth of all industrial sectors [13] Group 3: Pre-prepared Food Industry - The Chinese government is drafting national standards for pre-prepared foods to enhance consumer protection and industry quality [25][26] - The introduction of these standards is expected to raise compliance costs for smaller companies, leading to a market reshuffle favoring larger, established firms [27][28] - As industry standards improve, leading companies are likely to benefit from enhanced brand trust and market share [29] Group 4: Chemical Industry Developments - The Ministry of Ecology and Environment is pushing for the exit of outdated capacity in the chlor-alkali industry, particularly in PVC production, due to environmental concerns [31][32] - The implementation of the Minamata Convention will increase production costs for companies using mercury-based processes, accelerating the exit of less competitive firms [33] - Beneficiaries of these changes include companies like Xinjiang Tianye and Zhongtai Chemical, which are better positioned to adapt to the new regulatory environment [34] Group 5: Medical Industry Insights - Kailaiying, a leading small molecule CDMO, is transitioning towards a dual business model that includes emerging sectors like peptides and small nucleic acids, showing strong growth potential [35][36] - The company is expanding its peptide production capacity significantly to meet the rising demand for GLP-1 drugs, positioning itself favorably in a high-growth market [36] - The overall investment environment in the healthcare sector is improving, which may lead to increased demand for CDMO services [37]